Phoenix, AZ 的 過重 臨床試驗
15 項針對 過重 的研究正在 Phoenix（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
招募中3 期
- Absolute Clinical Research, Phoenix
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
招募中3 期
- RIO Clinical Trials - Phoenix, Phoenix
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
招募中3 期
- Research Site, Phoenix
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
招募中3 期
- Synexus Clinical Research US, Inc., Phoenix
- Medical Advancement Centers of Arizona, Phoenix
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
招募中3 期
- Elite Clinical Studies, LLC, Phoenix
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
招募中3 期
- AURORA-1 Clinical Site, Phoenix
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
招募中3 期
- AURORA-2 Clinical Site, Phoenix
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
招募中2 期
- Helios Clinical Research - Phoenix, Phoenix
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
招募中3 期歡迎健康志工
- ACCOMPLISH-2 Research Site, Phoenix
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
招募中2 期
- Synexus Clinical Research US, Inc., Phoenix
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
招募中4 期
- Medical Dermatology Specialists, Phoenix
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
招募中3 期
- Kailera Clinical Site, Phoenix
Redefining Evaluation of Adiposity and Leanness: Broadening Objective Diagnostics for Obesity
招募中觀察性研究
- Exponent Phoenix, Phoenix
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
招募中3 期
- ACCOMPLISH-1 Research Site, Phoenix
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
招募中3 期
- The University of Arizona College of Medicine- Phoenix, Phoenix
其他城市的 過重 試驗
- San Antonio, TX34 項研究
- Houston, TX33 項研究
- Chicago, IL28 項研究
- Orlando, FL27 項研究
- Las Vegas, NV23 項研究
- Miami, FL23 項研究
- Atlanta, GA20 項研究
- Dallas, TX20 項研究
- New York City, NY19 項研究
- Jacksonville, FL19 項研究
- Washington, DC19 項研究
- Austin, TX18 項研究
Phoenix 的其他研究
- 乳癌25 項研究
- 大腸直腸癌25 項研究
- 肥胖症22 項研究
- 非小細胞肺癌20 項研究
- 轉移性癌症20 項研究
- 心臟衰竭18 項研究
- 前列腺癌17 項研究
- 癌症（所有類型）17 項研究
- 多發性骨髓瘤16 項研究
- 胰臟癌16 項研究
- 心血管疾病16 項研究
- 阿茲海默症15 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月5日。各研究自行設定資格標準；由研究團隊決定參與者資格。